Aurobindo Pharma gets USFDA approval to make, market Bivalirudin injection
New Delhi: Aurobindo Pharma Limited said it got the approval of the US Food and Drug Administration (USFDA) to manufacture and market Bivalirudin injection of 250 mg/vial.
In a press release here, Aurobindo Pharma Ltd said the drug was a generic equivalent to the Angiomax injection.
The Bivalirudin injection was being used as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty among others, the release said.
The drug was intended for use with aspirin, it said.
Citing market reports, the release said the estimated market size of the Bivalirudin injection was USD 101 million for the year ending May 2018.
The product would be launched in September 2018, the release said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd